Successful outcome of ganciclovir-resistant cytomegalovirus infection in organ transplant recipients after conversion to mTOR inhibitors

Transpl Int. 2012 Jul;25(7):e78-82. doi: 10.1111/j.1432-2277.2012.01489.x. Epub 2012 May 11.

Abstract

Ganciclovir-resistant (GanR) cytomegalovirus (CMV) infection after organ transplantation is emerging as a significant therapeutic challenge. We report two cases of GanR CMV infection successfully managed by switching immunosuppression from calcineurin inhibitors to an mTOR inhibitor-based regimen. This salvage therapy should be considered when other options are not available.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / pharmacology
  • Calcineurin Inhibitors
  • Cytomegalovirus / metabolism*
  • Cytomegalovirus Infections / drug therapy*
  • Drug Resistance, Viral*
  • Ganciclovir / pharmacology*
  • Heart Transplantation / adverse effects
  • Humans
  • Immunosuppressive Agents / pharmacology*
  • Kidney Transplantation / adverse effects
  • Male
  • Middle Aged
  • Organ Transplantation / adverse effects
  • TOR Serine-Threonine Kinases / antagonists & inhibitors*
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Calcineurin Inhibitors
  • Immunosuppressive Agents
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • Ganciclovir